The NovaBridge Biosciences (NBP) SEC filings page on Stock Titan provides access to the company’s official disclosures as a foreign private issuer listed on Nasdaq. NovaBridge, formerly known as I-Mab, files reports such as Form 20-F and Form 6-K that describe its financial condition, risk factors, and operational progress as a global biotechnology platform company.
In these filings, NovaBridge outlines its business model, which combines business development and translational clinical development to advance a pipeline led by givastomig, ragistomig, uliledlimab, and VIS-101. Management’s discussion and analysis sections describe how the company allocates resources to oncology and ophthalmology programs, summarizes its collaborations with partners such as ABL Bio, and explains the structure of subsidiaries like Visara within its hub-and-spoke framework.
Investors reviewing NovaBridge’s SEC reports can examine clinical development disclosures for givastomig, including its positioning as a Claudin 18.2 x 4-1BB bispecific antibody in gastric and other gastrointestinal cancers, and for ragistomig as a PD-L1 x 4-1BB bispecific in solid tumors. Filings also discuss rights to uliledlimab outside Greater China and the VIS-101 license and assignment arrangements involving Visara and Everest Medicines.
Stock Titan enhances these regulatory documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as segment descriptions, collaboration agreements, share incentive plans, and subsequent events. Users can follow new 6-K submissions for interim updates, and consult annual filings for a more comprehensive view of NovaBridge’s strategy, risk profile, and pipeline.
By using this page, investors and researchers can monitor NovaBridge’s official SEC communications in real time, while AI-generated insights help interpret complex biotech and capital markets information contained in the original documents.
NovaBridge Biosciences (NBP) appointed Charles “Chuck” Silberstein, M.D., M.B.A., CFA, as chief financial officer, effective November 2, 2026. He succeeds Ming (Kyler) Lei, whose resignation is effective October 30, 2026; the company said Lei’s resignation did not result from any disagreement about its operations, policies or practices.
Silberstein brings more than 25 years across biotechnology leadership, corporate finance, capital markets, business development and healthcare investing. Before joining NovaBridge, he was co-founder and CEO of FytonBio through October 2026, and previously served as CFO of GentiBio and CFO and head of business development at Applied Therapeutics.
NovaBridge Biosciences (NBP) reported updated Phase 1b results for givastomig with nivolumab and chemotherapy in HER2-negative first-line metastatic gastroesophageal adenocarcinoma. The dataset covered 71 patients in the 8 mg/kg and 12 mg/kg cohorts; median follow-up in the 8 mg/kg cohort was 17.8 months. Among efficacy-evaluable patients at 8 mg/kg, the objective response rate was 79% (23/29), the disease control rate was 97% (28/29), median duration of response was 15.2 months and median progression-free survival was 16.9 months.
Response rates were 82% in patients with CLDN18.2 expression ≥75% and 75% in patients with expression between 1% and 74%. NovaBridge selected the 8 mg/kg dose for registrational development based on efficacy, safety and follow-up data. No Grade 4 or Grade 5 treatment-related adverse events were attributed to givastomig; immune-related adverse events were uncommon apart from gastritis, most of which were Grade 2. The company reported alignment with the FDA on a global registrational study protocol.
NovaBridge Biosciences (NBP) reported that clinical data from the ongoing Phase 1 clinical trial of ragistomig, also known as ABL503 or TJ-L14B, were presented by ABL Bio in a poster at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid on October 23, 2026. The poster concerned dose optimization; ragistomig is a bispecific antibody targeting PD-L1 and 4-1BB that NovaBridge and ABL Bio are jointly developing.
NovaBridge Biosciences director Ian Ying Woo reported converting 5,770 restricted share units into 5,770 ADSs on October 15, 2026. The ADSs correspond to 13,271 Ordinary Shares under the disclosed ratio of 10 ADSs for 23 Ordinary Shares. The reported post-transaction amounts were 11,540 ADSs for the restricted share units and 13,271 Ordinary Shares.
NovaBridge Biosciences (NBP) reported that its majority-owned ophthalmology subsidiary, Visara, entered an exclusive license agreement with Wuhan Hiteck Biological Pharma Co., Ltd. for worldwide development and commercialization of investigational VIS-102, excluding Greater China. Visara will pay Hiteck $7.0 million as an upfront and near-term milestone payment, plus additional payments of up to $104.0 million based on clinical development and commercialization milestones and tiered royalties at a single digit percentage of annual net sales.
In a Phase 1b study in Chinese subjects with severe neurotrophic keratitis, the highest-dose cohort had 50% complete corneal healing after an 8-week VIS-102 course; the vehicle control group had 14% complete healing at Week 4. After crossing over to VIS-102, participants from the vehicle group had 43% complete healing following a 4-week course. The study’s expansion phase will evaluate the highest dose at six times daily and three times daily in 8-week regimens.
NovaBridge Biosciences (NBP) reported that Chief Medical Officer Dennis Phillip Andrew exercised equity awards and sold a portion of his holdings. On September 17, 2026, he exercised 10,302 restricted share units, receiving 10,302 ADSs represented by 23,695 Ordinary Shares, bringing his position from this award to securities represented by 78,972 ADSs. On September 18, 2026, he sold 8,209 Ordinary Shares (represented by 3,569 ADSs) at $0.71 per Ordinary Share, corresponding to an ADS price of $1.6247, after which his reported holdings from this line were represented by 75,403 ADSs. No Rule 10b5-1 trading plan is indicated.
NovaBridge Biosciences (NBP) discloses that Chief Medical Officer Dennis Phillip Andrew filed a Rule 144 notice to sell 3,569 shares of common stock through Citigroup Global Markets on September 18, 2026 on NASDAQ. The shares relate to restricted stock vesting, with 10,302 shares noted as securities to be sold from compensation vesting on the same date. Over the prior three months, he reported selling 3,693 shares of common stock.
NovaBridge Biosciences (NBP) reported that Chief Business Development Officer Cao Sean Wuxiong sold 107,978 Ordinary Shares on September 9, 2026, at a reported converted price of $0.74 per Ordinary Share, leaving him with 266,467 Ordinary Shares held directly.
The footnotes state that the transaction involved 46,947 American Depositary Shares (ADSs) representing approximately 107,978 Ordinary Shares, sold in connection with the partial vesting of a restricted stock unit award on September 3, 2026, solely to satisfy tax withholding obligations. The reported sales price corresponds to an ADS price of $1.6908. No Rule 10b5-1 trading plan is reported.
NovaBridge Biosciences (NBP) reported the initial beneficial ownership status of director Dewhurst Martin William on a Form 3. The filing lists him as a director only and shows no reportable holdings or transactions in NovaBridge Biosciences equity securities at the time of this report.
NovaBridge Biosciences (NBP) received a notice under Rule 144 that Chief Business Development Officer Cao Sean Wuxiong plans to sell 46,947 Ordinary Shares through Citigroup Global Markets on or about September 9, 2026 on NASDAQ, with an aggregate market value of $79,377.99 and 265,377,891 shares outstanding.
The shares derive from restricted stock units vesting on September 3, 2026, when 147,554 shares were acquired as compensation, and the filing states that shares are being sold to cover obligations arising from the vesting and settlement of equity awards.